Morgan Stanley Cardiol Therapeutics Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 63,700 shares of CRDL stock, worth $81,536. This represents 0.0% of its overall portfolio holdings.

Number of Shares

63,700

Previous 27,300 133.33%

Holding current value

$81,536

Previous $55,000 129.09%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.83 - $2.48 $66,612 - $90,272	36,400 Added 133.33%	63,700 $126,000
Q2 2024 Aug 14, 2024	BUY	$1.67 - $2.97 $45,591 - $81,081	27,300 New	27,300 $55,000
Q3 2023 Nov 15, 2023	BUY	$0.76 - $1.19 $76 - $119	100 New	100 $0
Q4 2022 Feb 14, 2023	SELL	$0.48 - $1.0 $6,712 - $13,985	-13,985 Reduced 75.73%	4,482 $2,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.41 $12,917 - $17,856	12,664 Added 218.23%	18,467 $19,000
Q2 2022 Oct 27, 2022	BUY	$1.03 - $2.05 $1,342 - $2,671	1,303 Added 28.96%	5,803 $7,000
Q2 2022 Aug 15, 2022	BUY	$1.03 - $2.05 $1,342 - $2,671	1,303 Added 28.96%	5,803 $7,000
Q1 2022 Oct 27, 2022	SELL	$1.25 - $2.31 $1,628 - $3,009	-1,303 Reduced 22.45%	4,500 $7,000
Q1 2022 May 13, 2022	SELL	$1.25 - $2.31 $5,688 - $10,512	-4,551 Reduced 50.28%	4,500 $7,000
Q4 2021 Feb 14, 2022	SELL	$1.83 - $4.86 $33,011 - $87,669	-18,039 Reduced 66.59%	9,051 $17,000
Q3 2021 Nov 15, 2021	BUY	$2.03 - $4.8 $54,992 - $130,032	27,090 New	27,090 $112,000

Others Institutions Holding CRDL

# of Institutions

Shares Held

5.07M

Call Options Held

5.2K

Put Options Held

9.5K

View Full List

About Cardiol Therapeutics Inc.

Ticker CRDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 61,942,500
Market Cap $79.3M
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...

More about CRDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account